Tetrahydropalmatine

DB12093InvestigationalSmall molecule

Tetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity).

Formula / weight: C₂₁H₂₅NO₄ · 355.434 g/mol (avg)

Resolves to

Compound

UNII3X69CO5I79CAS483-14-7ChEMBLCHEMBL487182ChEBI16563PubChem72301KEGGC02890

Structure

InChIKeyAEQDJSLRWYMAQI-KRWDZBQOSA-NSMILESCOC1=CC=C2C[C@@H]3N(CCC4=CC(OC)=C(OC)C=C34)CC2=C1OC

Targets

P21728DRD1P14416DRD2

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,724Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tetrahydropalmatine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account